---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-010740"
form_type: "8-K"
ticker: "VIR"
cik: "0001706431"
company_name: "Vir Biotechnology, Inc."
filed_at: "2026-02-23T23:59:59+00:00"
generated_at: "2026-05-16T01:12:35.315312+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.95
calibrated_materiality_score: 0.95
confidence: "high"
source: SEC EDGAR
---

# Vir Biotechnology enters global strategic collaboration with Astellas for VIR-5500 prostate cancer T-cell engager

## Summary
- Vir Bio will receive $335 million in upfront and near-term payments, including $240M cash and $75M equity at 50% premium.
- Eligible for up to $1.37 billion in development, regulatory and sales milestones plus tiered double-digit royalties on ex-U.S. net sales.
- Global development costs shared 40% Vir Bio / 60% Astellas; U.S. profits/losses split 50/50 with Vir co-promotion option.
- Phase 1 data for VIR-5500 shows dose-dependent anti-tumor activity; oral presentation at ASCO GU 2026 on February 26.
- Cash and investments $781.6M as of Dec 31, 2025; net loss for full year 2025 was $438.0 million.

## SEC filing metadata
- accession: 0001628280-26-010740
- form_type: 8-K
- ticker: VIR
- cik: 0001706431
- company_name: Vir Biotechnology, Inc.
- filed_at: 2026-02-23T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.95
- calibrated_materiality_score: 0.95
- confidence: high
- sec_items: 1.01, 2.02, 3.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1706431/000162828026010740/0001628280-26-010740-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1706431/000162828026010740/vir-20260219.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-010740
- JSON: https://secwatch.observer/filing/0001628280-26-010740.json
- Plain text: https://secwatch.observer/filing/0001628280-26-010740.txt

## Source-grounded claims
- claim_id: 2e82a69080506ca159674129ebb1b998d5a851c7
  claim: Vir Biotechnology, Inc. entered into Collaboration and License Agreement with Astellas US LLC valued at $335 million in upfront and near-term milestone payments (effective 2026-02-19).
  evidence_excerpt: On February 19, 2026, Vir Biotechnology, Inc. (Vir Bio) and Astellas US LLC (together with its subsidiaries and affiliates (including its indirect parent, Astellas Pharma Inc.), Astellas) entered into a Collaboration and License Agreement (the Agreement).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1706431/000162828026010740/0001628280-26-010740-index.htm
- claim_id: 3ab58c2082c0337f6333f1ede5c2f6277aa94382
  claim: Vir Biotechnology, Inc. entered into Stock Purchase Agreement with Astellas US LLC valued at approximately $75 million (effective 2026-02-19).
  evidence_excerpt: Concurrently with the execution of the Agreement, Vir Bio also entered into the SPA, pursuant to which Astellas has agreed to purchase 7,239,382 shares of Vir Bio’s common stock, par value $0.0001 per share (Common Stock), for an aggregate purchase price of approximately $75 million, subject to customary closing conditions.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1706431/000162828026010740/0001628280-26-010740-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.